Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Current Deferred Revenue (2020 - 2025)

iSpecimen has reported Current Deferred Revenue over the past 6 years, most recently at $192535.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $192535.0 for Q4 2025, down 46.62% from a year ago — trailing twelve months through Dec 2025 was $192535.0 (down 46.62% YoY), and the annual figure for FY2025 was $192535.0, down 46.62%.
  • Current Deferred Revenue for Q4 2025 was $192535.0 at iSpecimen, up from $155506.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ISPC hit a ceiling of $802860.0 in Q2 2021 and a floor of $46910.0 in Q3 2023.
  • Median Current Deferred Revenue over the past 5 years was $271444.5 (2024), compared with a mean of $323280.5.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 82.79% in 2023 and later soared 504.5% in 2024.
  • iSpecimen's Current Deferred Revenue stood at $654746.0 in 2021, then plummeted by 79.79% to $132335.0 in 2022, then soared by 214.18% to $415771.0 in 2023, then dropped by 13.24% to $360708.0 in 2024, then tumbled by 46.62% to $192535.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $192535.0 (Q4 2025), $155506.0 (Q3 2025), and $164066.0 (Q2 2025) per Business Quant data.